ArticleNanotheranostics2025
Doxorubicin-NFL-TBS.40-63 peptide Gold Complex Nanovector (DOX IN-NFL@AuNPs): Efficacy Evaluation in a mouse transplantation tumor model induced by PANC-1/ADR human pancreatic cancer resistant strain cells.
Article in Nanotheranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The key role of the NFL-TBS.40-63 peptide (BIOT-NFL) is to target and destroy glioma cancer cells. Recently we have performed a novel peptide-hybrid-gold nanovector (BIOT-NFL-PEG-AuNPs) capable to destroy microtubule network of pancreatic cancer cells (PDAC) exhibiting a decrease of tumor index with a real anti-angiogenic effect. In order to improve the scientific background of our study, we conceived a chemotherapeutic hybrid nanovector based on gold-doxorubicin (DOX) functionalized with the NFL-TBS.40-63 peptide (BIOT-NFL) as a promising therapeutic in PDAC cancer. Mouse transplantation tumor model induced by PANC-1/ADR human pancreatic cancer resistant strain cells, was used to evaluated the therapeutic efficacy of DOX IN-NFL@AuNPs as chemotherapeutic nano-drug. Our results indicate that DOX IN-NFL@AuNPs have a great impact on the decrease of the tumor growth and decreased the tumor index with a relevant effect on cytokines and ROS levels, thus confirming the impact of DOX IN-NFL@AuNPs to boost the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.